Cancer Medicine (Nov 2022)

Identification of FDFT1 as a potential biomarker associated with ferroptosis in ccRCC

  • Ruizhen Huang,
  • Chiyu Zhang,
  • Xing Wang,
  • Xin Zou,
  • Zhengjie Xiang,
  • Zewei Wang,
  • Bin Gui,
  • Tao Lin,
  • Honglin Hu

DOI
https://doi.org/10.1002/cam4.4716
Journal volume & issue
Vol. 11, no. 21
pp. 3993 – 4004

Abstract

Read online

Abstract Renal cell carcinoma (RCC) seriously threatens people's lives and health. The identification of some precise biomarkers during the process of RCC progression and the pathophysiologic procedure is critical for improving the diagnosis and management of RCC. Evidence suggests that ferroptosis may play a pivotal role in eradicating clear cell RCC (ccRCC, KIRC) tumor cells. We screened out the target prognostic ferroptosis‐associated genes and examined the functions of farnesyl‐diphosphate farnesyltransferase (FDFT1) in 786‐O cells by plasmid transfection. In our study, we identified FDFT1 as a potential marker correlating with ferroptosis in KIRC. Upregulated FDFT1 inhibited cell proliferation, migration, and invasion, and the underlying antitumor effects may occur via the AKT signaling pathway. Our study provides helpful evidence to study the complex physiopathology of KIRC.

Keywords